A next-generation cancer vaccine has shown stunning results in mice, preventing up to 88% of aggressive and ...

A new research paper was published in Volume 16 of Oncotarget on October 6, 2025, titled "ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL ...

Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with relapsing forms of MS.

ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in ...

Progression-free and overall survival outcomes in patients with cancer treated with immunotherapy could be related to thymic ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human ...

Oncologi, Inc., a biotechnology company developing next-generation RNA-based cancer immunotherapies, today announced that the ...

In cancer patients, the health of the thymus—a key part of the body's immune system—is associated with the outcomes these ...

“Our new model mimics human foetal blood development in the lab. This sheds light on how blood cells naturally form during ...

University of Cambridge scientists have used human stem cells to create three-dimensional embryo-like structures that ...

The statements regarding Herpafend have not been evaluated by the Food and Drug Administration (FDA). This product is not ...